The 2026 MIPS measures for dermatology practices are important for eligible clinicians participating in Medicare’s Quality Payment Program (QPP). Dermatologists must understand applicable quality measures, reporting requirements, documentation standards, and performance categories to maintain accurate reporting and manage potential Medicare payment adjustments.
For dermatology practice owners, successful MIPS reporting requires coordination between clinical documentation, electronic health records (EHRs), coding workflows, and quality reporting processes.
2026 MIPS Performance Categories and Scoring
Traditional MIPS evaluates eligible clinicians across four performance categories. Each category contributes to the final MIPS score, although special statuses and reporting exceptions may change the standard weights.
| Performance Category | 2026 Weight | Reporting Requirements |
| Quality | 30% | Report six quality measures or a complete applicable specialty set. |
| Cost | 30% | CMS calculates performance using Medicare administrative claims data. |
| Promoting Interoperability | 25% | Report required measures using certified EHR technology (CEHRT), generally for at least 180 continuous days. |
| Improvement Activities | 15% | Generally complete two qualifying activities for at least 90 continuous days. |
For 2026, the MIPS performance threshold is 75 points. Clinicians scoring below this threshold may receive a negative Medicare Part B payment adjustment, while scores above it may qualify for a positive adjustment. The payment adjustment based on 2026 performance applies in 2028.
These requirements should also be considered as part of a practice’s broader dermatology revenue cycle management processes, where clinical documentation, coding, billing, and administrative workflows need to work together.
11 MIPS Quality Measures Relevant to Dermatology in 2026
The 2026 dermatology specialty measure set includes 11 quality measures, eight of which are classified as high priority. These measures address medication documentation, biologic therapy safety, preventive screening, referral coordination, psoriasis management, pathology communication, and melanoma follow-up.
The following measures are relevant to dermatology practices reviewing their 2026 reporting options.
| Quality ID | MIPS Quality Measure | What Dermatology Practices Should Monitor |
| 130 | Documentation of Current Medications in the Medical Record | Maintain an accurate medication list, including prescriptions, OTC products, supplements, dosage, frequency, and route. |
| 176 | Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy | Document appropriate TB screening before initiating eligible biologic or immune response modifier therapy. |
| 226 | Tobacco Use: Screening and Cessation Intervention | Document tobacco-use screening and appropriate cessation intervention for identified tobacco users. |
| 317 | Screening for High Blood Pressure and Follow-Up Documented | Record blood pressure screening and the appropriate follow-up plan when readings are elevated. |
| 374 | Closing the Referral Loop: Receipt of Specialist Report | Track referrals and ensure the referring clinician receives the specialist’s report. |
| 410 | Psoriasis: Clinical Response to Systemic Medications | Monitor and document clinical response to systemic psoriasis medications. |
| 440 | Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician | Monitor the time required for pathology results to reach the clinician following a qualifying skin biopsy. |
| 485 | Psoriasis – Improvement in Patient-Reported Itch Severity | Track changes in patient-reported itch severity for psoriasis. |
| 486 | Dermatitis – Improvement in Patient-Reported Itch Severity | Monitor patient-reported itch severity and improvement in dermatitis. |
| 503 | Gains in Patient Activation Measure (PAM) Scores at 12 Months | Monitor changes in patient activation scores over the specified 12-month period. |
| 509 | Melanoma: Tracking and Evaluation of Recurrence | Maintain documentation supporting melanoma recurrence tracking and evaluation. |
Important: Being included in the dermatology specialty measure set does not automatically make every measure applicable to every practice. Measure selection depends on clinician eligibility, patient populations, denominator requirements, available benchmarks, and the permitted reporting method.
2026 MIPS Quality Reporting Requirements
Dermatology practices reporting through Traditional MIPS generally need to select six quality measures, including at least one outcome or high-priority measure, or report a complete applicable specialty measure set.
Several reporting requirements deserve particular attention:
75% Data Completeness: Practices must submit performance data for at least 75% of denominator-eligible cases for each reported quality measure. The requirement generally applies across eligible patients regardless of payer, including Medicare, Medicaid, and commercial insurance.
20-Case Minimum: Most quality measures require at least 20 denominator-eligible cases to receive measure achievement scoring, subject to measure-specific exceptions.
Full-Year Performance Period: The 2026 quality performance period runs from January 1 through December 31, 2026.
Accurate Documentation: Practices should ensure that clinical records, medication lists, referral reports, pathology communications, and other measure-specific information are complete and available for reporting.
Traditional MIPS vs. Dermatological Care MVP
Dermatologists may also consider the Dermatological Care MIPS Value Pathway (MVP), a specialty-focused reporting option.
Unlike Traditional MIPS, which generally requires six quality measures or a complete applicable specialty set, the Dermatological Care MVP requires at least four quality measures from its applicable measure set, including an outcome or high-priority measure.
| Reporting Requirement | Traditional MIPS | Dermatological Care MVP |
| Quality measures | Six or complete specialty set | At least four applicable measures |
| High-priority or outcome measure | Required | Required |
| Data completeness | 75% | 75% |
| Minimum cases | Generally 20 | Generally 20 |
The 2026 Dermatological Care MVP requires advance registration through CMS. The registration period runs from April 1 through November 30, 2026. Practices considering this reporting option should verify their eligibility and registration requirements before the deadline.
Common MIPS Reporting Challenges for Dermatology Practices
Dermatology practices may encounter reporting problems when clinical records, billing information, and quality reporting workflows are not properly coordinated.
Common operational challenges include:
- Incomplete clinical documentation: Missing medication details, screening information, or follow-up records can affect quality measure reporting.
- Biologic therapy documentation: Missing TB screening records can create problems when monitoring eligible patients starting biologic treatment. Practices should also maintain consistent documentation to support payer reviews and reduce avoidable dermatology biologic claim denials.
- Referral tracking gaps: Referral orders may be recorded without confirmation that the referring clinician received the specialist report.
- Pathology communication delays: Incomplete tracking of biopsy reporting can affect the documentation needed for applicable quality measures.
- EHR data inconsistencies: Incomplete or inconsistent records can create challenges when identifying eligible encounters and preparing reporting data.
- Incomplete patient populations: Failure to identify denominator-eligible cases can affect the 75% data completeness requirement.
Addressing these issues requires coordination between clinicians, practice administrators, billing teams, and the staff responsible for quality reporting.
How Medical Billing and RCM Teams Can Support Dermatology Practices
Medical billing and revenue cycle management teams play an important supporting role in maintaining accurate administrative and financial workflows.
A dermatology-focused RCM partner can help practices with:
- Accurate coding and claim submission for documented services.
- Encounter and claim reconciliation.
- Identification of missing billing information and documentation discrepancies.
- Denial management and accounts receivable follow-up.
- Customized reporting to help practice administrators monitor revenue-cycle performance.
Practices reviewing procedure-level coding workflows can also refer to our 2026 dermatology CPT coding guide for information on common dermatology procedures and their coding considerations.
These services can support operational consistency, but clinical measure validation, MIPS eligibility decisions, and official quality data submission must remain coordinated with the responsible clinicians and qualified reporting professionals.
At CloudRCM Solutions, we help dermatology practices streamline medical billing, coding, denial management, and revenue cycle operations so providers can reduce administrative burdens and maintain better visibility into their financial performance.
Looking for dermatology billing support? Contact CloudRCM Solutions to discuss medical billing and revenue cycle management services for your practice.
FAQ’s
How many MIPS quality measures must dermatologists report in 2026?
Under Traditional MIPS, eligible clinicians generally report six quality measures, including at least one outcome or high-priority measure, or a complete applicable specialty measure set. The Dermatological Care MVP generally requires at least four quality measures.
What is the MIPS data completeness requirement for 2026?
The 2026 quality reporting data completeness threshold is 75% of denominator-eligible cases for each reported measure. The requirement generally applies regardless of payer.
What is the 2026 MIPS performance threshold?
The 2026 MIPS performance threshold is 75 points. A final score below 75 may result in a negative Medicare Part B payment adjustment for 2028.
Does the MIPS Cost category require separate data submission?
No. CMS calculates the Cost performance category using Medicare administrative claims data. Clinicians do not submit separate cost-category data.
Is every dermatology practice required to participate in MIPS?
No. Participation depends on MIPS eligibility, clinician type, Medicare billing activity, and applicable exclusions or special statuses. Practices should verify their eligibility through the CMS Quality Payment Program.
What is the difference between Traditional MIPS and the Dermatological Care MVP?
Traditional MIPS provides a broader reporting framework across four performance categories. The Dermatological Care MVP organizes reporting around a specialty-specific pathway with a defined set of quality measures, activities, and cost measures.
Information reviewed November 2026. MIPS eligibility, measure specifications, reporting options, and submission requirements should be confirmed against the applicable CMS and AAD guidance before reporting.

Medical Billing
Medical Coding
Medical Audit
Provider Credentialing
Denial Management
A/R Follow-up
Private Practice
Patient Help Desk
Customized Reporting
Out-of-Network Billing
Internal Medicine
Pediatrics
Radiology
Surgery
Emergency Medicine
Anesthesiology
Cardiology
Orthopedic
Psychiatry
Dentistry
OB-GYN
Family Medicine


